Clinical trials: Neoplasms, Prostatic
Prostate Cancer
Transrectal Photoacoustic Imaging of the Prostate
The purpose of this study is to image human prostate tissue using a new transrectal photoacoustic imaging probe and correlate this with ultrasound and MRI imaging performed once the specimen has been surgically removed.
- Trial name
- NCT02365883
- Testing
- Photoacoustic Imaging System
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Carcinoma of Prostate
PSMA PET Registry (18F-DCFPyL)
The purpose of the Princess Margaret Cancer Centre PSMA registry is to assess the contribution of 18F-DCFPyL (PSMA) PET imaging (PET/MR or PET/CT) to the management of patients with prostate cancer (PCa).
- Trial name
- PM-PPR (NCT03535831)
- Testing
- 18F-DCFPyL
- Where
- Canada
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Prostate Cancer Adenocarcinoma in Situ
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
This research is being done to see if an investigational prostate cancer vaccine, called GVAX, can safely be given together with a single intravenous injection of a drug called cyclophosphamide to men that will undergo surgery to…
- Trial name
- NCT01696877
- Testing
- degarelix acetate, Cyclophosphamide, GVAX
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Prostate Adenocarcinoma
68Ga-PSMA-11 PET in Patients With Prostate Cancer
Patients will receive a single dose of 68Ga-PSMA-11 and undergo a PET/CT or PET/MRI imaging study.
- Trial name
- NCT05197257
- Testing
- Ga-PSMA-11
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- University of Colorado, Denver
Prostate Cancer Metastatic
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
PEACE-6 Poor Responders is an international, multicenter, open-label, controlled, randomized, phase III trial to evaluate the efficacy and safety of 177Lu-PSMA-617 when administered on top of the ongoing standard systemic…
- Trial name
- NCT06496581
- Testing
- 177Lu-PMSA-617, Standard of Care
- Where
- 25 sites in France
- Volunteers
- 500 people
- Sponsor
- UNICANCER
Lymphocele, Prostate Cancer
Ultrasound Guided Inguinal Indocyanine Green Injection to Identify and Pre-emptively Seal Lymphatic Leaks
Goal is to determine whether intraoperative ICG injection can be used to identify and reduce formation of symptomatic lymphoceles in patients receiving robot-assisted prostatectomy.
- Trial name
- NCT06258486
- Testing
- ICG injection, Non-Injection/Control, Prostatectomy with pelvic lymph node dissection
- Volunteers
- 100 people
- Sponsor
- Kaiser Permanente
Prostatic Neoplasms
Prostate Cancer Biobank
Carcinoma of the prostate is the second most commonly diagnosed cancer and occurs predominantly in older men - almost two-thirds of those affected are over 65 years of age.
- Trial name
- NCT04024475
- Testing
- Observation
- Where
- 12 sites in Switzerland
- Volunteers
- 1,323 people
- Sponsor
- Swiss Cancer Institute
Prostate Cancer
Development and Validation of Novel MRI Methods for the Detection of Prostate Cancer Aggressiveness
The purpose of this study is to develop, validate, and evaluate the correlation of novel magnetic resonance imaging (MRI) methods with prostate cancer aggressiveness and histological data obtained during prostatectomy.
- Trial name
- PROAG (NCT02545881)
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- Finland
- Volunteers
- 200 people
- Sponsor
- Turku University Hospital
Prostate Cancer, Opioid Use
Post-Discharge Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery
ORIOLES is a non-randomized, pre-post intervention study designed to improve quality of opioid prescribing and use after discharge for patients undergoing urologic surgery.
- Trial name
- ORIOLES (NCT03536065)
- Testing
- Opioid Reduction Intervention, Current Care
- Where
- United States
- Volunteers
- 443 people
- Sponsor
- Johns Hopkins University
Prostate Cancer
The Accuracy of Modified TTMB in the Spatial Distribution of Prostate Cancer
Investigators plan to use modified TTMB technology to puncture prostate of participants suspected prostate cancer, especially those with the first negative biopsy , but having a rising PSA.Then, Investigators will simulate the…
- Trial name
- NCT03418207
- Testing
- trans-perineal template-guided mapping biopsy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Subei People's Hospital of Jiangsu Province
Intraprostatic Prostate Cancer
Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
The purpose of this study is to assess the impact of prostate-specific membrane antigen/positron emission tomography (PSMA/PET)-informed magnetic resonance (MR)-guided radiation therapy on serious toxicity outcomes in patients…
- Trial name
- NCT07142967
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Androgen Deprivation Therapy (ADT)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- NYU Langone Health
Metastatic Castration-Resistant Prostate Cancer Patients
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
The study seek to evaluate the anti-tumor effect after treatment of Irofulven in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic…
- Trial name
- NCT03643107
- Testing
- Irofulven, Prednisolone 10 mg
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Allarity Therapeutics
Prostate Cancer
High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)
The purpose of this study is to find out the effects (good and bad) of using newer technologies that allow very precise delivery of radiation.
- Trial name
- SIB (NCT02177292)
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Medical College of Wisconsin
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC
This is a single-arm, single-center, open-label clinical trial designed to evaluate the clinical safety and tolerability of different doses of Prostate-Specific Membrane Antigen (PSMA)-Universal Chimeric Antigen Receptor (UCAR)…
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT06895811
- Testing
- PSMA-UCAR T (BRL-302)
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai Changzheng Hospital
Preference, Patient, Pharmacist-Patient Relations
Preferences of Patients Treated With Oral Cancer Drugs and Informal Caregivers for Pharmaceutical Consultation in Hospital
To ensure the safe use of oral anticancer drugs, oncology pharmacy consultations (OPCs) have been established in France. Their goal is to provide the patient with the means to identify, prevent and limit adverse effects and to…
- Conditions
- Preference, Patient, Pharmacist-Patient Relations, Caregiver, Cancer
- Trial name
- IMPLICATION (NCT05970471)
- Where
- France
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hormone-refractory Prostate Cancer
Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
The aim of the present feasibility study of a new short palliative radiotherapy regime that apply to patients with metastatic hormone refractory prostate cancer (HRPC) presenting with a dominating debilitating symptom.
- Trial name
- PRADO (NCT03658434)
- Testing
- Palliative radiotherapy
- Where
- 3 sites in Denmark, Germany
- Volunteers
- 34 people
- Sponsor
- Zealand University Hospital
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO
This study is a prospective, observational, molecular stratification profiling study. Patients with mCRPC who have received at least one standard treatment for mCRPC will be approached to participate in MAESTRO.
- Trial name
- MAESTRO (NCT03934164)
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Cancer
Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer
The aim of this study is to confirm the Efficacy,the Safety and the Quality of Life after TOOKAD® Soluble VTP in localized prostate cancer patients.
- Trial name
- PCM304 (NCT01875393)
- Testing
- TOOKAD® Soluble
- Where
- 3 sites in Mexico, Panama and 1 more
- Volunteers
- 81 people
- Sponsor
- Steba Biotech S.A.
Prostate Cancer
Prostate Screening Study Using MRI in BRCA Carriers
Men with a BRCA1 or BRCA2 mutation are at increased risk for early onset, aggressive prostate cancer compared to men in the general population.
- Trial name
- NCT01990521
- Testing
- MS3TMRI / TRUS Guided Biopsy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Toronto Sunnybrook Regional Cancer Centre
Prostate Cancer, Recurrent Prostate Carcinoma
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with hormone-resistant prostate cancer that has spread to other places in the body and express androgen receptor-variant-7 (AR-V7).
- Conditions
- Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
- Trial name
- STARVE-PC (NCT02601014)
- Testing
- Ipilimumab, Nivolumab, Enzalutamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins